Introduction
Reoperation after breast-conserving surgery (BCS) for breast cancer (BC) could be proposed for positive or close margins. Guidelines for reoperation have evolved during the past years: for invasive BC, margins ≥5 mm and then 2 mm and "no ink on tumor" are required, and for ductal carcinoma in situ (DCIS), margins ≥2 mm are usually required.
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Reoperation type, re-excision or mastectomy, depends on several factors in relation to patient's and pathological tumor characteristics, mainly 1) patient's choice informed of third reoperation risk and no postmastectomy radiotherapy (PMRT) for patients without axillary lymph node macrometastases; 2) breast size, tumor size, and tumor localization; and 3) possibility of surgical resection (ie, oncoplasty).
Several studies have reported reoperation rate and type of reoperation after BCS, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] but only a few focused on predictive factors determining reoperation type. 11, 13, 16 We have analyzed institutional BC database in order to determine rates and associated factors for reoperation, mastectomy, and third reoperation.
Patients and methods
All patients undergoing BCS in our institution, between January 1995 and December 2017, were included, except those with cT4 and inflammatory BC. A process is in place for institutional BC database to ensure data integrity, accuracy, and completeness. Reoperation rate and type of reoperation rates (re-excision or mastectomy) and second reoperation after re-excision were analyzed. Factors associated with reoperation, mastectomy, and third intervention were determined. We analyzed interval times between first surgery and reoperation for DCIS, for invasive BC with distinction between patients with or without AC. Overall survival and disease-free survival were compared between patients with and without reoperation.
BCS was undertaken with systematic resection from the subcutaneous layer to major pectoralis muscle and cutaneous resection when tumor was near the skin or when cutaneous retraction was observed. The specimen was pinned on a plate, oriented, and lateral margins inked.
We performed literature review in order to discuss these results.
statistics
Univariate comparisons were performed using chi-square test. To assess the independent prognostic effect of the variables, a multivariable analysis, using binary logistic regression, was performed. The multivariable model was fitted for those factors that were statistically significant in the univariate analyses. ORs and 95% CIs were estimated for each variable compared to the reference group. Survivals results were compared using the log-rank test. A two-sided P-value of <0.05 was considered as statistically significant. Data analysis was performed using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA).
Results
Patients
A total of 10,761 patients were included in the analysis: 1,161 DCIS and 9,600 invasive BC. The characteristics of patients are reported in Table 1 .
Reoperation
Reoperation rate was 29.4% (3,168/10,761: 95% CI 28.5-30.3): 41.4% (481/1,161) and 28.0% (2,687/9,600) for DCIS and invasive BC, respectively. For the total cohort, all factors analyzed were significantly different for reoperation rate in the univariate analysis (Table 1 ). In the multivariate analysis for DCIS, tumor size ≥20 mm increased reoperation rate and age >50 years, P2-3 periods, and tumor localization (upper superior quadrant and external superior and inferior quadrants) decreased reoperation rates (Table 2 ). In multivariate analysis for invasive BC, lobular tumor, bifocal or multifocal tumors, presence of lymphovascular peritumoral invasion (LVI), DCIS component, and Her2-positive tumors increased reoperation rates and age >40 years, triple-negative tumors, NAC, and noncentral tumors decreased reoperation rates (Table 3) .
Reoperation type
For patients, who needed reoperation, a mastectomy was performed at first reoperation in 51.9% (1,645/3,168; 241/481: 50.1% for DCIS and 1,404/2,687: 52.2% for invasive BC) and mastectomy was required after first reoperation with re-excision in 13.46% (205/1,523: 35 for DCIS and 170 for invasive BC) with a total mastectomy rate of 58.4% (1,850/3,168; 276/481: 57.4% for DCIS and 1,574/2,687: 58.6% for invasive BC). For DCIS, the mastectomy rate was higher for grade 2 tumors and tumor sizes ≥20 mm (Table 4) . For invasive BC, the mastectomy rate was higher for lobular tumors, bifocal or multifocal tumors, tumor sizes ≥20 mm, Her2-positive tumors, and diffuse positive margins and lower for age >50 years and patients treated during the last period ( Among patients with re-excision, factors associated with reoperation with mastectomy in binary logistic regression were tumor size ≥20 mm; multifocal tumors, which increased mastectomy rates; and age >50 years, which decreased mastectomy rates (Table 6 ).
interval time
The median interval time between first surgery and reoperation for DCIS was 35 days (mean: 44.58, 95% CI 41.3-47.8) and 78 days for patients with a second reoperation (mean 90.9, 95% CI 75.9-105.8). Median interval time between first operation and radiotherapy for patients with DCIS was 55 days (mean 63, 95% CI 60.4-65.6) and for patients with re-excision (n = 238) or no reoperation (n = 562), it was 77 days (mean 89.8, 95% CI 83.4-96.1) or 47 days (mean 51.7, 95% CI 49.8-53.6), respectively.
The median interval time between first surgery and reoperation (first reoperation) for invasive BC was 29 days (mean 47.7, 95% CI 39.6-55.8) and 123 days for patients with a second reoperation (mean: 133, 95% CI 121-145). When AC was administered, reoperation was performed before or after chemotherapy. The median interval time between first surgery and reoperation for invasive BC was 28 days (mean 33, 95% CI 31.8-34.1) for patients without any treatment before reoperation (AC after reoperation or patients with previous NAC or patients without AC before reoperation) and 173.5 days (mean 179, 95% CI 174-184) for patients with AC before reoperation.
The median time interval between first operation and radiotherapy for patients with invasive BC without AC was 73 days (mean 142 days, 95% CI 14-270) and 46 days for patients with or without reoperation (mean 47.3 days, 95% CI 46-48), respectively.
For patients with invasive BC and AC, the median interval time between first operation and AC was 42 days (mean 47.3 days, 95% CI 45.8-48.9) and 34 days (mean 36.9 days, 95% CI 36-38) for patients with reoperation and without reoperation, respectively, and the median interval time between first operation and radiotherapy was 188 days (mean 186.5 days, 95% CI 184-189) and 167 days (mean 158 days, 95% CI 156-160) for patients with reoperation and without reoperation, respectively.
survival
The median follow-up was 53.2 months (95% CI 56.7-89.0 months). Overall survival and disease-free survival were not different between patients with and without reoperation (log-rank test: 0.393 and 0.963 for invasive BC and 0.212 and 0.231 for DCIS). Abbreviations: DCis, ductal carcinoma in situ; BC, breast cancer; eiQ, external inferior quadrants; iiQ, internal inferior quadrant; esQ, external superior quadrant; isQ, internal superior quadrant; eeQ, equatorial external quadrant; einfQ, equatorial inferior quadrant; eintQ, equatorial internal quadrant; esupQ, equatorial superior quadrant.
10,761 patients Total Reoperation
c2
DCIS Reoperation
Discussion
In our study, the reoperation rate for DCIS was high (41.4%) but lower during the two last periods (decrease of 24.6%), and higher mastectomy rates (49.9%) were reported for tumors ≥20 and <50 mm. These results are concordant with literature results. 17 Higher reoperation rates were also observed in the literature survey results for lobular carcinomas. The reoperation rate for invasive BC was 28.0%, higher for young patients, triple-negative and Her2-positive tumors, lobular carcinomas, and multifocal tumors and lesser after NAC. Higher mastectomy rates for reoperation were also observed in our study mainly for these same factors. However, NAC was proposed for patients who need mastectomy before NAC or for patients with aggressive tumors (ie, SBR grade 3, Her2-positive, triple negative) and axillary involvement at ultrasonography and percutaneous biopsy.
In literature review, the mean reoperation rate (re-excision or mastectomy) was 27.49% (95% CI 27.4-27.6, range: 10.2%-34%) among 402,357 patients with BC (DCIS or invasive) operation. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Re-excision rates for BCS are extremely variable across the literature. This is mainly due to no clear consensus regarding the definition of a negative margin, different preoperative and intraoperative tumor localizing methods, differences in intraoperative imaging techniques, specimen inking by surgeons or pathologists, the use of shave margins, tumor vs lumpectomy size, oncoplastic resections, volume of breast surgery per year by surgeons, and surgeon threshold to offer re-excision vs mastectomy for positive margins. 13, 18, 19 When analysis of reoperation rates was performed according to three periods of treatment, we observed a decrease in reoperation rates among successive periods from 28.96% (4, Abbreviations: BC, breast cancer; eiQ, external inferior quadrant; iiQ, internal inferior quadrant; esQ, external superior quadrant; isQ, internal superior quadrant; inf M fold, inferior mammary fold; eeQ, equatorial external quadrant; einfQ, equatorial inferior quadrant; eintQ, equatorial internal quadrant; esupQ, equatorial superior quadrant; naC, neoadjuvant chemotherapy; lVi, lymphovascular peritumoral invasion; DCis, ductal carcinoma in situ; iT, intratumoral.
However, reoperation rates differed between histological types of invasive BC: 26.98% for ductal invasive BC, 40.6% for lobular invasive BC, and 21.83% for others invasive histological types. 2 For DCIS, there was no statistically significant difference in locoregional recurrence (LRR) for patients with margins <2 versus ≥2 mm who received radiotherapy (10-year LRR 4.8% vs 3.3%, respectively; P = 0.72). 20 One other large study evaluating the relationship between margin width and recurrence did not identify a significant association of recurrence with margin width of ≤2 mm compared with larger margins for patients receiving radiotherapy. 21 However, Morrow et al 
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houvenaeghel et al reported in 2016 that 2 mm margin minimizes the risk of ipsilateral breast tumor recurrence (IBTR) compared with smaller negative margins, using a meta-analysis of margin width and IBTR from a systematic review. A conservative reoperation was done in ~50% of patients with DCIS or ductal invasive BC and lesser for lobular invasive BC (~30%) with a decrease in mastectomy rates among successive periods analyzed. In our study, interval times between first surgery and adjuvant treatments increased for patients who needed reoperation but without significant impact on survival.
A third intervention for mastectomy had been reported in three studies, 1, 3, 6 and in our study: mastectomy rate after re-excision was 13.54% (1,059/7,818, 95% CI 12.8-14.3). Mastectomy rates among 108,446 patients with reoperation in the literature review were 40.77% (95% CI 40.5-41.1, range: 10.7-62.1) and 55.4% (95% CI 54.6-56.2) for studies with analysis of a third intervention for mastectomy (8,309/14,998 ). 1, 3, 6 When analysis of mastectomy rates was performed according to the three periods of treatment (DCIS and invasive), we observed a decrease in mastectomy rates among successive periods from 59.62% (2,739/4,594, 95% CI 58.2-61.0) to 48.8% (2,532/5,191, 95% CI 47.4-50.2) and 36.81% (6,892/17,903, 95% CI 36.1-37.5). 3, 4, 6, 7, 9, 11 In the After initial oncoplastic surgery, close or positive margins was reported in 12.3% (342/2,772, 95% CI 11.1-13.5) of patients in a meta-analysis reported in 2014, 23 and the mastectomy rate for reoperation after initial oncoplastic resection was high: 64% in Clough et al's 24 study and 61.3% in Losken et al 23 meta-analysis. Interval time between surgery or first surgery for patients who need reoperation and adjuvant treatment: even if interval time was higher for patients with reoperation, we did not observe impact on survival results between patients with or without reoperation.
Conclusion
A decrease of reoperation rate and mastectomy rate in future years is probably in relation with negative margin resection without several mm of margin, more accurate preoperative radiologic analysis, particularly for lobular and multifocal tumors; more oncoplastic resections; and more NAC. A third intervention with mastectomy was required in about 13%-14% of patients. Information about risk of a third intervention should be given to patients who require reoperation.
Even if interval time between surgery and adjuvant treatments was higher for patients with reoperation, survival results were not different between patients with and without reoperation.
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